Slide 1: Strategic Update January 2025
Strategic Update January 2025 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to financial measures prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), from time to time we may use or publicly disclose certain non-GAAP financial measures in the course of our financial presentations, earnin
Slide 4: Stronger Together
STRONGER together 233,000 Unique Patients Treated 8,280,000 Treatments Administered $135M annual revenue (2023) Two of the nation’s largest mental health and device companies are now combined to create an organization with the ability to leverage its scale and capabilities to treat more patients suf
Slide 5: A Diversified Business Model with Strategic Advantages from Combined Expertise
A Diversified Business Model with Strategic Advantages from the Company’s Combined Expertise Creates a vertically integrated organization providing greater access to mental health treatments through our collective expertise NeuroStar Market Leader in TMS Greenbrook Mental Health Services Provider La
Slide 6: A Compelling Investment Opportunity
A Compelling Investment Opportunity Combines the U.S.’s most utilized therapeutic platform with the largest service provider to renew even more lives The NEW
Slide 7: Over 29 Million People Can Benefit from NeuroStar TMS
Over 29 Million People Can Benefit from NeuroStar TMS U.S. Adults and Adolescents (ages 15-21) suffering from depression, depression with anxiety, and OCD Total Available Market 29.3 million Nearly 8 million patients are poorly served by antidepressant medication Lack of Treatment Efficacy Intolerab
Slide 8: Key Growth Initiatives for Greenbrook Clinics
Key Growth Initiatives for Greenbrook Clinics Excellence in Execution, Profitable Product Diversification & Expansion Expanding the Continuum of Care for Patients Identifying and Educating Patients Consistent Implementation of Best Operation Practices
Slide 9: Key Growth Initiatives for NeuroStar Customer Sites
Key Growth Initiatives for NeuroStar Customer Sites Harnessing the Power of our Proven Programs to Help More Patients in Need Expand BMP Network Patient Education Expanding Services to Existing Customers
Slide 10: Significant Realized Cost Synergies
Dollars in $M Significant Realized Cost Synergies Fully Executed Expected 1H 2025
Slide 11: Improved Financial Profile Adds Scale and Strength
Improved Financial Profile Adds Scale and Strength 4Q 2024 Neuronetics Adjusted Gross Pro Forma Revenue $19.5M Intercompany Eliminations ($2.4M) Neuronetics Adjusted Net Pro Forma Revenue $17.1M Preliminary Greenbrook Gross Revenue $18.5M Impact of Greenbrook Clinic Closures ($0.9M) Greenbrook Net P
Slide 12: Poised to Deliver Mid-Teens Growth and Profitability
Poised to Deliver Mid-Teens Growth and Profitability FY 2025 Guidance Revenue $145M to $155M (+12% to +19% Pro Forma YoY) Gross Margin Approximately 55% Operating Expenses $90M - $98M Profitability Cash flow positive beginning in Q3 2025
Slide 13: Non-GAAP Financial Measures (Unaudited)
Non-GAAP Financial Measures (Unaudited) 4Q 2024 FY 2024 (in millions) (in millions) Consolidated revenue $ 22.1 $ 74.5 Greenbrook revenue (post-acquisition period) $ (3.7) $ (3.7) Neuronetics standalone revenue $ 18.4 $ 70.8 Greenbrook intercompany revenue (post-acquisition period) $ 0.6 $ 0.6 Assum